Document Type : Original Article



BACKGROUND: The angiotensin‑converting enzyme 2 (ACE2) receptor, a membrane receptor
present in the respiratory system, the gastrointestinal tracts, the heart, and the kidney is the entry
point for SARS‑CoV‑2 to enter human cells. Concerns were raised about the influence of using
antihypertensive drugs like angiotensin‑converting enzyme inhibitors (ACEIs) or angiotensin receptor
blockers (ARBs) in individuals with COVID‑19 due to its tight relationship with the ACE2 receptor. The
aim of this study was to investigate the impact of being on an Angiotensin Receptor Blockers (ARB)
on mortality in patients consecutively diagnosed with COVID‑19.
MATERIAL AND METHODS: This is the retrospective observational study done in all patients
consecutively diagnosed with COVID‑19 from January 2021 to June 2021. All related patient
information and clinical data was retrieved from the hospitals electronic medical record system.
RESULTS: In this study, out of 500 patients, 51 died, having mean age of 66.92 ± 10.85 years.
144 (28.8%) patients were on angiotensin receptor blockers as antihypertensive treatment,
142 (28.4%) having other antihypertensive and 214 (42.8%) were not on any treatment. Out of 51
Death 7 (4.9) patients were on ARBs, 15 ± 10.6 were on other medication [OR 2.31 (0.94–6.22,
P = 0.077) univariable; OR 2.57 (1.00–7.23, P = 0.058) multivariable] and 29 ± 13.6 had no treatment
at all [OR 3.07 (1.38–7.80, P = 0.010) univariable; OR 3.36 (1.41–9.08, P = 0.010) multivariable].
CONCLUSION: Use of ARB medications for the hypertensive patients who acquire COVID‑19
infection has shown protective effects of such medications on COVID‑19 disease severity in the
term of mortality and the mortality rate among hypertensive patients on COVID‑19 with ARBs/ACE
inhibitors showed significant differences as compared to other antihypertensives.


1. Lake MA. What we know so far: COVID‑19 current clinical
knowledge and research. Clin Med (Lond) 2020;20:124‑7.
2. Wu F, Zhao S, Yu B, Chen Y, Wang W, Hu Y, et al. Complete
genome characterisation of a novel coronavirus associated with
severe human respiratory disease in Wuhan, China. bioRxiv 2020.
doi: 10.1101/2020.01.24.919183.
3. Zhou P, YangX, WangX, Hu B, Zhang L, ZhangW, et al. Discovery
of a novel coronavirus associated with the recent pneumonia
outbreak in humans and its potential bat origin. bioRxiv 2020.
doi: 10.1101/2020.01.22.914952.
4. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al.
Angiotensin‑converting enzyme 2 protects from severe acute
lung failure. Nature 2005;436:112‑6.
5. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB,
Tallant EA, et al. Effect of angiotensin‑converting enzyme
inhibition and angiotensin II receptor blockers on cardiac
angiotensin‑converting enzyme 2. Circulation 2005;111:2605‑10.
6. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID‑19 infection?
Lancet Respir Med 2020;8:e21.
7. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid
advice guideline for the diagnosis and treatment of 2019 novel
coronavirus (2019‑nCoV) infected pneumonia (standard version).
Mil Med Res 2020;7:4. doi: 10.1186/s40779‑020‑0233‑6.
8. Wösten‑van Asperen RM, Lutter R, Specht PA, Moll GN,
van Woensel JB, van der Loos CM, et al. Acute respiratory distress
syndrome leads to reduced ratio of ACE/ACE2 activities and
is prevented by angiotensin‑(1–7) or an angiotensin II receptor
antagonist. J Pathol 2011;225:618‑27.
9. Kumar S, Acharya S, Jain S, Shukla S, Talwar D, Shah D, et al. Role
of zinc and clinicopathological factors for COVID‑19‑associated
mucormycosis (CAM) in a rural hospital of central India:
A case‑control study. Cureus 2022;14:e22528. doi 10.7759/cureus.
10. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features
of patients infected with 2019 novel coronavirus in Wuhan, China.
Lancet 2020;395:497‑506.
11. Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical
characteristics of imported cases of COVID‑19 in Jiangsu province:
A multicenter descriptive study. Clin Infect Dis 2020;71:706‑12.
12. Tetlow S, Segiet‑Swiecicka A, O’Sullivan R, O’Halloran S, Kalb K,
Brathwaite‑Shirley C, Alger L, Ankuli A, Baig MS, Catmur F,
Chan T, Dudley D, Fisher J, Iqbal MU, Puczynska J, Wilkins R,
BygateR, Roberts P. ACE inhibitors, angiotensin receptor blockers
and endothelial injury in COVID‑19. J Intern Med. 2021 May;
289(5):688‑699. doi: 10.1111/joim. 13202.
13. BraudeP, CarterB, ShortR, Vilches‑MoragaA, VerduriA, PearceL,
et al. The influence of ACE inhibitors and ARBs on hospital length
of stay and survival in people with COVID‑19. Int J Cardiol Heart
Vasc 2020;31:100660. doi: 10.1016/j.ijcha. 2020.100660.
14. Senkal N, Meral R, Medetalibeyoglu A, Konyaoglu H, Kose M,
Tukek T. Association between chronic ACE inhibitor exposure
and decreased odds of severe disease in patients with COVID‑19.
Anatol J Cardiol 2020;24:21‑9.
15. Zhou F, Liu YM, Xie J, Li H, Lei F, Yang H, et al. Comparative
impacts of ACE (Angiotensin‑Converting Enzyme) inhibitors
versus angiotensin ii receptor blockers on the risk of COVID‑19
mortality. Hypertension 2020;76:e15‑7.
16. Bean DM, Kraljevic Z, Searle T, Bendayan R, Kevin O, Pickles A,
et al. Angiotensin‑converting enzyme inhibitors and angiotensin
II receptor blockers are not associated with severe COVID‑19
infection in a multi‑site UK acute hospital trust. Eur J Heart Fail
17. Flacco ME, Acuti Martellucci C, Bravi F, Parruti G, Cappadona R,
Mascitelli A, et al. Treatment with ACE inhibitors or ARBs
and risk of severe/lethal COVID‑19: A meta‑analysis. Heart
18. Talwar D, Kumar S, Acharya S, Raisinghani N, Madaan S,
Hulkoti V, et al. Interleukin 6 and its correlation with COVID‑19
in terms of outcomes in an intensive care unit of a rural hospital:
A cross‑sectional study. Indian J Crit Care Med 2022;26:39‑42.
19. Marashizadeh A, Sanati HR, Sadeghipour P, Peighambari MM,
Moosavi J, Shafe O, et al. Left ventricular end‑diastolic
pressure‑guided hydration for the prevention of contrast‑induced
acute kidney injury in patients with stable ischemic heart disease:
The LAKESIDE trial. Int Urol Nephrol 2019;51:1815‑22.
20. Sadeghipour P, Talasaz AH, Rashidi F, Sharif‑Kashani B,
Beigmohammadi MT, Farrokhpour M, et al. Effect of
Intermediate‑Dose vs Standard‑Dose Prophylactic Anticoagulation
on Thrombotic Events, Extracorporeal Membrane Oxygenation
Treatment, or Mortality Among Patients With COVID‑19
Admitted to the Intensive Care Unit: The INSPIRATION
Randomized Clinical Trial. JAMA. 2021 Apr 27;325(16):1620‑1630.
doi: 10.1001/jama. 2021.4152